End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.92 CNY | +0.25% | -1.17% | -3.32% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Weaknesses
- With an expected P/E ratio at 45.03 and 34.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.32% | 780M | - | ||
-0.41% | 1.84B | B- | ||
-7.40% | 1.79B | C+ | ||
+8.67% | 1.06B | - | ||
-14.95% | 1.02B | - | C- | |
-11.35% | 1.02B | B | ||
-7.85% | 914M | B | ||
-4.79% | 861M | B- | ||
-2.23% | 778M | - | - | |
+7.20% | 654M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301206 Stock
- Ratings Shandong Sanyuan Biotechnology Co.,Ltd.